One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And ... MarketWatch (press release) NATICK, Mass., May 15, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces that the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in ... |
